 |
| Research article summary (published 18 Jun 2003): |
A multicenter, randomized, placebo controlled, multiple-dose, safety and pharmacokinetic study of AIT-082 (Neotrofin) in mild Alzheimer's disease patients.
Full Abstract
A phase 1, randomized, double-blind, placebo-controlled, dose escalation study of the purine derivative, AIT-082 (Neotrofin, NeoTherapeutics) was conducted in mild Alzheimer's disease (AD) patients to evaluate multiple-dose safety, tolerability, and pharmacokinetics. Possible short-term effects of AIT-082 on cognition and memory were preliminarily investigated. AIT-082 is currently being developed as a potential treatment for Alzheimer's disease and other neurological disorders. Pre-clinical studies indicate that AIT-082 has memory enhancing properties, stimulates neuritogenesis and the production of neurotrophic factors. Patients received an oral dose of AIT-082 or placebo daily for one week. Thirty-six AD patients were divided into three dose cohorts; each dose cohort consisted of twelve patients with 8 patients randomized to AIT-082 and 4 to placebo. The 3 doses of AIT-082 evaluated in this study were 100 mg/day, 500 mg/day, and 2,000 mg/day. There were no serious adverse events at any dose and the drug was well tolerated without significant side effects. AIT-082 was orally and rapidly absorbed, resulting in peak serum concentrations within 2 hours with an elimination half-life of approximately 20 hours. Higher doses resulted in corresponding increases in peak concentrations and areas under the curve (AUC). There was an approximate 2-fold accumulation in AIT-082 with daily dosing (as reflected by the AUC) at steady state. There were no significant differences by treatment arm on the clinical or neuropsychological evaluations. AIT-082 was rapidly absorbed by the oral route with a half-life suitable for dosing once or twice daily. No problems with tolerability or safety were found. AIT-082 appears suitable for testing in larger clinical trials for the treatment of AD and other neurologic disorders.
Learn Faster Today Improve your study skills
Author information
Author/s: Grundman, M (M); Capparelli, E (E); Kim, H T (HT); Morris, J C (JC); Farlow, M (M); Rubin, E H (EH); Heidebrink, J (J); Hake, A (A); Ho, G (G); Schultz, A N (AN); Schafer, K (K); Houston, W (W); Thomas, R (R); Thal, L J (LJ); Alzheimer's Disease Cooperative Study;
Affiliation: Department of Neurosciences, University of California-San Diego, 9500 Gilman, La Jolla, CA 92093, USA. mgrundman(-atsign-)ucsd.edu
Grants: M01 RR 00827 (Agency:United States NCRR) ; P50 AG 05131 (Agency:United States NIA) ; U01 AG 10483 (Agency:United States NIA)
Journal and publication information
Publication Type: Clinical Trial; Clinical Trial, Phase I; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
Journal: Life sciences (Life Sci), published in England. (Language: eng)
Reference: 2003-Jun; vol 73 (issue 5) : pp 539-53
Dates: Created 2003/05/28; Completed 2003/06/26; Revised 2007/11/14;
PMID: 12770610, status: MEDLINE (last retrieval date: 11/6/2008)
Sourced from the National Library of Medicine. Abstract text and other information may be subject to copyright.
External Links for this article (including full text providers, if available):
Click Electronic Full-text Provider Links to see options for finding the electronic full text links to this article. Note there may be a subscription or fee required for access to the full text. See our FAQ for information on finding FREE full text articles.
This article may also be located in paper journal collections available in many libraries. Use the Journal and Publication Information above to find the full article.
MeSH headings (categories)
This article was linked to the MESH Headings shown below.
|
|
Related articles
This article has not been indexed for related articles as yet, however you can still use the live related article search links below.
See a large map of 100+ related articles.